Docoh
Loading...

ARQT Arcutis Biotherapeutics

News

Pro users get this 30m faster
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep 21
Biotech, Earnings, M&A, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29)
Arcutis Biotherapeutics Highlights New Patent Issued By US Patent & Trademark Office 'covering its invention for improving delivery and extending half-life of both the cream and foam formulations of topical roflumilast'
28 Sep 21
News, Legal
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with
Arcutis Biotherapeutics to Present Data At European Academy of Dermatology and Venereology (EADV) Congress.
27 Sep 21
Biotech, News, Small Cap, Events, General
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with
Arcutis Biotherapeutics Sponsored Study Titled 'A Randomized tRial Employing topiCal roflumilasT Foam to Treat Scalp Psoriasis (ARRECTOR) (ARRECTOR)' Posted To ClinicalTrials.gov; Study Not Yet Recruiting
31 Aug 21
News, FDA
https://clinicaltrials.gov/ct2/show/NCT05028582
Arcutis Biotherapeutics Q2 EPS $(0.84) Up From $(0.94) YoY
5 Aug 21
Earnings, News
Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly losses of $(0.84) per share. This is a 10.64 percent increase over losses of $(0.94) per share from the same period last year.

Press releases

Pro users get this 30m faster
New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress
30 Sep 21
News, Press Releases, General
Topical roflumilast provided significant improvements in severity and burden of itch in Phase 3 plaque psoriasis studies, as well as Phase 2 studies in seborrheic dermatitis and scalp and body psoriasis.Quality of life
Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent
28 Sep 21
Press Releases
WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to
New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress
27 Sep 21
News, Press Releases
WESTLAKE VILLAGE, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to
Arcutis to Present at Upcoming Investor Conferences
9 Sep 21
News, Health Care, Press Releases
WESTLAKE VILLAGE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to
Arcutis Announces Appointment of Keith Leonard to Board of Directors
2 Sep 21
News, Management, Press Releases
WESTLAKE VILLAGE, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address the urgent needs